Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

OBJECTIVE

The impact of CYP2A6*21 (K476R) on in vivo nicotine metabolism and disposition was investigated.

METHODS

A two-step allele-specific PCR assay was developed to detect the 6573A>G single nucleotide polymorphism (SNP) in CYP2A621. Nicotine metabolism phenotypes from a previously described intravenous labeled nicotine and cotinine infusion study [1] was used to assess the impact of CYP2A621. Genomic DNA samples from 222 (111 monozygotic and dizygotic twin pairs) Caucasian subjects were genotyped for CYP2A6 alleles (CYP2A6*1X2, -*1B, -*2, -*4, -*7, -*9, -*10, -12, and -21). The pharmacokinetic parameters were compared between individuals with no detected CYP2A6 variants (CYP2A61/1, n = 163) and individuals heterozygous for the CYP2A621 allele (CYP2A61/*21, n = 9).

RESULTS

The frequency of the CYP2A621 allele was found to be 2.3% in Caucasians (n = 5/222 alleles, evaluated in one twin from each twin pair). In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A61/1, n = 163) and those with the variant (CYP2A61/*21, n = 9), respectively.

CONCLUSIONS

CYP2A621 does not have a detectable impact on nicotine metabolism in vivo. Our data suggest that CYP2A621 may not be important for future studies of nicotine metabolism and the resulting impacts on smoking behaviors.